Tag: rare-disease
Ironwood Pharmaceuticals Stock Analysis: Buy or Sell? FCF, Valuation, Pipeline
Ironwood Pharmaceuticals (IRWD) is rated Hold as LINZESS continues to generate real free cash flow, but apraglutide has faced delays and the stock already reflects much of the progress. The main debate is whether cash generation can offset LINZESS concentration and the 2027 Medicare price reset.